Skip to main content

Table 3 Serum level of soluble HLA-G antigens in ulcerative colitis and Crohn’s disease distributed according to some characteristics of patients

From: Susceptibility role of soluble HLA-G and HLA-G 14-bp insertion/deletion polymorphism in inflammatory bowel disease

Characteristic

sHLA-G (mean ± SD); ng/ml

p (pc)

UC (N = 30)

CD (N = 30)

 

Gender

 Male

192.0 ± 24.1

173.5 ± 25.1

0.005 (0.050)

 Female

170.5 ± 26.2

164.9 ± 27.5

0.542 (NS)

p (pc)

0.003 (0.030)

0.292 (NS)

 

Cigarette smoking status

 Smoker

187.9 ± 24.2

162.8 ± 25.9

0.004 (0.040)

 Non-smoker

165.9 ± 27.9

175.0 ± 26.2

0.419 (NS)

p (pc)

0.033 (NS)

0.181(NS)

 

Disease duration (years)

 ≤ 3

175.1 ± 32.2

164.9 ± 24.0

0.362 (NS)

 > 3

184.1 ± 23.4

172.9 ± 28.7

0.233 (NS)

 

0.376 (NS)

0.417 (NS)

 

Family history

 Yes

193.3 ± 31.7

174.7 ± 23.4

0.332 (NS)

 No

178.6 ± 26.5

167.8 ± 27.2

0.152 (NS)

p (pc)

0.352 (NS)

0.647 (NS)

 

Disease extension

 Ulcerative proctitis

185.4 ± 32.3

  

 Left-sided colitis

170.2 ± 19.3

  

 Extensive colitis

182.6 ± 25.0

  

 Ileocecal

 

171.6 ± 25.2

 

 Ileo-colonic

 

155.3 ± 30.5

 

p (pc)

0.457 (NS)

0.212 (NS)

 

Abdominal/or colon pain

 Present

184.7 ± 29.9

165.1 ± 23.6

0.030 (NS)

 Absent

169.1 ± 12.5

174.0 ± 29.7

0.662 (NS)

p (pc)

0.558 (NS)

0.841 (NS)

 

Diarrhea

 Present

184.6 ± 23.1

165.0 ± 27.6

0.032 (NS)

 Absent

172.3 ± 33.6

171.9 ± 25.8

1.000 (NS)

p (pc)

0.224 (NS)

0.485 (NS)

 

Fever

 Present

192.3 ± 27.0

169.4 ± 28.7

0.051 (NS)

 Absent

171.6 ± 24.2

168.6 ± 25.5

0.725 (NS)

p (pc)

0.040 (NS)

1.000 (NS)

 

Medication

 Protocol A

191.9 ± 23.6

167.6 ± 32.7

0.085 (NS)

 Protocol B

189.7 ± 26.3

159.8 ± 10.3

0.079 (NS)

 Protocol C

167.5 ± 15.3

181.8 ± 19.2

0.199 (NS)

 Protocol D

170.8 ± 32.0

165.2 ± 29.4

0.741 (NS)

p (pc)

0.119 (NS)

0.184 (NS)

 

Adalimumab or infliximab doses

 0

189.7 ± 26.3

159.8 ± 10.3

0.079 (NS)

 1–10

185.6 ± 23.7

172.8 ± 28.1

0.229 (NS)

 11–20

176.6 ± 24.6

161.2 ± 26.8

0.193 (NS)

 21–30

156.5 ± 47.5

197.8 ± 11.5

0.217 (NS)

p (pc)

0.334 (NS)

0.144 (NS)

 
  1. Significant p is bold-marked
  2. SD standard deviation, UC ulcerative colitis, CD Crohn’s disease, protocol A anti-inflammatory and immunosuppressive, protocol B anti-inflammatory and antibiotics, protocol C anti-inflammatory, immunosuppressive, and antibiotics, protocol D immunosuppressive only, p LSD (least significant) or one-way ANOVA (analysis of variance) probability, pc Bonferroni-corrected probability, NS not significant (pc > 0.05)